|
Found 47 result(s) FROM 1963 pages containing the term 'ESR'.
Tuesday Nov 17, 2009
Inflammation in RA Linked to Arterial Stiffness
RA patients with high inflammatory burden are more likely to have arterial stiffness, even without other known cardiovascular risk factors...
Friday Jun 26, 2009
Gum Disease Prominent in RA, but TNF-Blockade Can Help
Three new studies shed light on the connection between rheumatoid arthritis (RA) and periodontitis, and new data help define a role for TNF-blockade in improving periodontal status as well as RA signs and symptoms...
Tuesday Jun 23, 2009
MMF Effective, Safe for Proliferative as well as Membranous Lupus Nephritis
Mycophenolate mofetil (CellCept) may be as effective as, yet safer than, cyclophosphamide for the proliferative lupus glomerulonephritis...
Friday Apr 17, 2009
Naltrexone May Offer Low-Cost Help for Fibromyalgia
Low doses of naltrexone provided significant pain relief in a pilot study in fibromyalgia...
Thursday Feb 26, 2009
Pfizer Stops Work on Esreboxetine for FM
Pfizer has stopped development of esreboxetine, which was in phase II trials for fibromyalgia...
Wednesday Feb 04, 2009
Anakinra Shows Modest Benefit, Some Risk in RA: Cochrane Review
The IL-1 receptor antagonist Anakinra (Kineret, Amgen) significantly improves rheumatoid arthritis (RA) patients but may be less effective than other biologicals...
Thursday Nov 13, 2008
Il-6 Blockade Helps Move RA Patients TOWARD Remission
Interleukin-6 blockade with tocilizumab (Actemra®), when combined with conventional DMARDs, safely and effectively reduces rheumatoid arthritis joint and systemic symptoms in patients were not helped by DMARDs alone...
Thursday Oct 30, 2008
Old Malaria Drug Reduces Diabetes Risk in RA, Protects Kidneys in Lupus
The inexpensive old drug hydroxychloroquine (HCQ) shows remarkable protective ability against diabetes in patients with rheumatoid arthritis and against renal disease in patients with lupus...
Wednesday Oct 29, 2008
Lupus Kidney Failure Rate Skyrocketing in Black Women
For the first time, African Americans, who comprise 13% of the US population, account for nearly half of all cases of kidney failure due to systemic lupus erythematosus (SLE). Most affected are black women, whose risk of end-stage renal disease due to lupus nephritis is nearly 10 times that of white women...
Thursday Jun 19, 2008
Infliximab (Remicade®) Plus Combination DMARD Therapy for Early RA Increases Remission Rate, Slows Radiological Progression
Adding infliximab (INF) to effective combination DMARD therapy for patients with early RA both increases the remission and slows progression of joint damage...
Wednesday Jun 11, 2008
How to Tell If an RA Patient is Likely to Achieve DMARD-Free Remission Without Biologics
A number of factors identify rheumatoid arthritis patients whose disease is likely to respond to conventional DMARD treatment with sustained, drug-free remission...
Wednesday Jun 04, 2008
Case Series Adds Support for Routine PET in Polymyalgia Rheumatica
Routine PET might be a useful option in patients with steroid-resistant polymyalgia rheumatica (PMR)...
Friday May 02, 2008
Icelandic and British Researchers ID Five New Osteoporosis Genes
New research spotlighting five genetic loci associated with bone mineral density (BMD) and fractures may provide insight into the biochemical pathways that underlie osteoporosis…
Friday Dec 14, 2007
New Kid on the Block: Everolimus Looks Promising as Rheumatoid Arthritis Treatment
A "proof-of-concept" study shows that the immunosuppressant everolimus may be an effective addition to MTX for rheumatoid arthritis patients whose disease is only partly MTX-responsive...
Wednesday Nov 14, 2007
Fish Oil May Improve Symptoms and Endothelial Function in SLE
Omega-3 fish oil may reduce lupus disease activity and improve endothelial function...
Thursday Nov 08, 2007
Half of RA Patients Might Reach Remission With Early, Aggressive Use of Conventional DMARDs
If inflammatory arthritis is detected early and treated vigorously, remission is a possibility for 50% of patients...
Thursday Aug 02, 2007
TNF Inhibitors May Restore Adrenal Function in RA
TNF inhibitors appear to improve adrenal function in some RA patients, resulting in restoration of stable hormonal homeostasis...
Tuesday Jul 17, 2007
Prospective Study Validates ESR and CRP as Screening Tests for Infection Before Revision Total Knee Arthroplasty
ESR and CRP can be used to differentiate infected from noninfected knees prior to revision total knee arthroplasty…
Monday Jul 09, 2007
P&GP and Dong Wha Form Osteoporosis Alliance
Procter & Gamble Pharmaceuticals, Inc, a subsidiary of Procter & Gamble, and Dong Wha Pharmaceutical Ind Co, a leading Korean pharmaceutical company, announced a strategic alliance under which P&GP will have rights to develop and commercialize Dong Wha's novel class of molecules for the treatment of osteoporosis, including the drug DW 1350 and a family of backup compounds...
Wednesday Jun 27, 2007
Roche and Toyama Chemical Execute Agreement to Develop and Commercialize an Inhibitor of the Transcription Factor AP-1 (Activator Protein-1) to Treat RA
Roche Pharmaceuticals and Toyama Chemical Co, Ltd announced that they have entered into a licensing agreement for the worldwide research, development, and commercialization of Toyama's rheumatoid arthritis (RA) agent T-5224, an orally bioavailable inhibitor of the transcription factor AP-1 (Activator Protein-1).
Thursday Jun 07, 2007
Leflunomide Trumps MTX for Preventing Relapse in Wegener's Granulomatosis; Side Effects Still a Worry
A head-to-head comparison of leflunomide and MTX for Wegener's granulomatosis was stopped early due to higher relapse rates with MTX...
Monday Jun 04, 2007
Switching to Rituximab May Be Best Call If TNF-Blockers Fail in RA
Switching RA patients to rituximab after inadequate response to TNF inhibitors may be better than trying yet another anti-TNF agent...
Tuesday Apr 03, 2007
Inflammation More Important Than Joint Damage in Psoriatic Arthritis Disability
Psoriatic arthritis disease activity is more important than joint damage in causing disability, especially in the early years of disease duration…
Thursday Mar 29, 2007
FDG-PET Does Not Predict PMR Relapse But Does Show Inflammation of Processi Spinosi
FDG-PET did not help identify polymyalgia rheumatica (PMR) patients at high risk for relapse but did reveal a high level of inflammation of the processi spinosi, a novel finding that might help explain the morning stiffness reported by so many PMR patients...
Thursday Jan 11, 2007
Combination DMARD Therapy Leads to Sustained Remission in RA
Treating rheumatoid arthritis (RA) with a combination of disease modifying antirheumatic drugs (DMARDs) plus prednisolone results in sustained remission and blocks the progression of radiographic joint damage in a "remarkable proportion" of patients...
Tuesday Nov 07, 2006
Study IDs Predictors of Poor Outcome in Enthesitis-Related Arthritis
Enthesitis-related arthritis (ERA) patients tend to have worse outcomes than children with other subtypes of juvenile idiopathic arthritis (JIA). Predictors of poor outcome include family history of related diseases, the presence of HLA-DRB1*08, the absence of a protective HLA subtype, and persistently elevated erythrocyte sedimentation rate (ESR)…
Monday Oct 30, 2006
Neurochem Submits Complete Response to US FDA Approvable Letter for Eprodisate (KIACTAâ„¢) for the Treatment of Amyloid A Amyloidosis
Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc, headquartered in Québec, Canada, announced that it has submitted a complete response to the US FDA approvable letter for eprodisate (1,3-propanedisulfonate, Kiacta™, formerly Fibrillex™), an oral investigational product candidate for the treatment of amyloid A (AA) amyloidosis.
Tuesday Sep 26, 2006
New Markers Predict Lupus Kidney, Heart Risks
Cholesterol, homocysteine, and hs-CRP show promise as markers for elevated risk in lupus patients. Tisseverasinghe A, et al. Arthritis Rheum. 2006; 54:2211-2219; Von Feldt JM, et al. Arthritis Rheum. 2006; 54:2220-2227; Karadag O, et al. Clin Rheumatol. 2006; [Epub ahead of print]
Monday Sep 25, 2006
Rituximab Quickly Reduces Disease Activity in Treatment-Resistant RA
Rituximab added to methotrexate significantly reduces disease activity in patients whose RA is resistant to TNF inhibitors... Cohen SB, et al. Arthritis Rheum. 2006;54:2793-2806.
Monday Aug 28, 2006
Etanercept Maintains Clinical Benefit for Patients Who Must Drop Infliximab
Patients who respond to infliximab but must discontinue due to side effects maintain clinical benefit if switched to etanercept...
Thursday Aug 17, 2006
Early Diagnosis of AS: Dr. Rudwaleit Does the Math to Make It Easy
Diagnosing early ankylosing spondylitis in a patient with chronic back pain may be easier with a simple method based on standard tests and symptoms... Rudwaleit M, et al. Ann Rheum Dis. 2006;65:1251-1252.
Monday Jul 24, 2006
RA Patients with Persistently High ESR Rate at Greater Risk for Heart Failure
Rheumatoid arthritis with persistently elevated erythrocyte sedimentation rate values are at especially high risk of heart failure and should be monitored accordingly... Maradit-Kremers H, et al. Ann Rheum Dis. Published Online First: 3 July 2006. doi:10.1136/ard.2006.053710
Thursday Apr 27, 2006
Rheumatologists Rely on Swollen Joint Counts When Deciding to Change RA Therapy
Rheumatologists rely on swollen joint count, morning stiffness, and CRP levels when deciding to change RA therapy... Soubrier M, et al. J Rheumatol. 2006 Apr 15; [Epub ahead of print]
Tuesday Feb 14, 2006
Disease Activity and Severity Seen as Determinants in Starting Tumor Necrosis Factor-Alpha Blockers in Ankylosing Spondylitis Prior to Publication of ASAS Recommendations
Both disease activity and severity were determinants in starting tumor necrosis factor-alpha blockers in ankylosing spondylitis patients prior to the publication of the 2003 Assessment in AS (ASAS) international working group recommendations... Pham T, et al. Ann Rheum Dis [serial online]. February 7, 2006; doi:10.1136/ard.2005.042630
Wednesday Nov 16, 2005
REFLEX Trial Demonstrates Efficacy of Rituximab in RA Resistant to Anti-TNF Therapy
Rituximab, an anti-CD20+ B-cell-targeted monoclonal antibody with an established therapeutic record in the treatment of non-Hodgkin's lymphoma, has shown statistically significant and clinically meaningful improvement in rheumatoid arthritis (RA) patients who are refractory to anti-tumor necrosis factor-alpha (TNF-α) therapy... Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Monday Oct 24, 2005
Studies Outline Weaknesses of DAS28 as Rheumatoid Arthritis Assessment Tool
Two new studies add to a growing body of evidence suggesting that the disease activity score-28 (DAS28), a tool often used to determine the intensity of antirheumatic therapy, is not an appropriate gauge of remission in rheumatoid arthritis (RA).
Friday Aug 05, 2005
RA Patients With High BMI Have Lower Mortality
In a finding that runs contrary to the recognized relationship between increased weight and mortality, a new study has found that rheumatoid arthritis (RA) patients with a high body mass index had a lower risk of death than their leaner counterparts... Escalante A, Haas RW, del Rincón I. Arch Intern Med. 2005;165:1624-1629.
Monday Jun 13, 2005
IL-6 Blocker Shows Promise in Systemic Onset Juvenile Idiopathic Arthritis
More evidence emerging on the therapeutic potential of the experimental IL-6 blocker tocilizumab in the management of severe SJIA... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Friday Jun 10, 2005
High Doses of All NSAIDs Reportedly Increase Heart Attack Risk
The largest study to date on the association between cardiovascular events and the use of NSAIDs has found that the increase in risk is not limited to selective inhibitors of COX-2, and that, in fact, some nonselective NSAIDs confer the greatest risks...Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Thursday Jun 09, 2005
Dr. Gary Williams Weighs in on the Coxib Controversy
Gary Williams MD, PhD, chairman of the department of medicine at Scripps Clinic Medical Group, and co-chair of the symposium Clarifying the Risk/Benefit of COX-2 Selective Inhibitor Use at the 6th EULAR Annual European Congress of Rheumatology, spoke with CIAOMed on Wednesday regarding the current controversy over the fate of the COX-2 inhibitors
Thursday Jun 09, 2005
A Conversation at EULAR: Dr. Ricard Cervera on Biologics and Pregnancy
The preeminent immunologist comments on the increasing use of TNF-α inhibitors and other biologic drugs-particularly among women, who bear the brunt of autoimmune disease-and the concern about their potential effects on pregnancy... Cervera R. Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Thursday Jun 09, 2005
Trials Examine Efficacy and Safety of B-cell Depletion in RA
Favorable results from the DANCER trial and other studies of rituximab suggest that this anti-CD20 monoclonal antibody may be a promising therapy, particularly for refractory patients... Emery P, et al. Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Tuesday Mar 22, 2005
IL-6 Blocker "Promising" in Systemic Onset Juvenile Idiopathic Arthritis
Small study demonstrating efficacy and safety of MRA in juvenile arthritis, combined with promising results in treatment of other conditions, suggests that IL-6 inhibitors may play an important role in controlling inflammatory disease...Yokota S, et al. Arthritis Rheum. 2005;52:818-825.
Sunday Mar 13, 2005
Markers of Systemic Inflammation May Be Independent Risk Factors for Cardiovascular Death in Patients With Rheumatoid Arthritis
A new study indicates that ESR may be predictive of CV mortality and suggests that tighter control of inflammation may help improve long-term outcomes for RA patients...Maradit-Kremers H, et al. Arthritis Rheum. 2005;52:722-732.
Wednesday Feb 23, 2005
New Findings Confirm Predictive Power of Cyclic Citrullinated Peptide Antibodies in Patients With Very Early Rheumatoid Arthritis
Study offers further evidence that the presence of antibodies to CCP in addition to RF in patients with early inflammatory arthropathy can forecast the development of RA... Raza K, et al. J Rheumatol. 2005;32:231-238.
Monday Nov 15, 2004
New Approaches Show Promise in Refining Treatment and Assessment of SLE
Autologous stem cell transplant and rituximab show promise in refractory disease, and the erythrocyte sedimentation rate test may be more useful than CRP in showing disease activity... Alexander T et al. Presented at: Annual Meeting of the American College of Rheumatology; October 19, 2004; San Antonio, Tex.
Wednesday Jun 09, 2004
Genome-wide Approaches Shed New Light on the Genetic Control of Arthritis
This session, on the opening day of EULAR 2004, revealed insight into the genetic control of osteoarthritis and rheumatoid arthritis.
|
